Related Experiment Video
Updated: Jul 6, 2026

12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Published on: January 17, 2015
Screening isolates from antibody phage-display libraries
David R Buckler1, Albert Park, Malini Viswanathan
1Dyax Corp., 300 Technology Square, Cambridge, MA 02139, USA. dbuckler@dyax.com
Drug Discovery Today
|April 15, 2008
Summary
Automated screening of antibody phage display libraries accelerates drug lead discovery. Efficiently managing phage screening data by linking isolate behavior to DNA sequencing is crucial for identifying potent therapeutic candidates.
Area of Science:
- Biotechnology
- Immunology
- Drug Discovery
Background:
- Antibody phage display is a powerful technique for identifying therapeutic antibodies from large combinatorial libraries.
- Automated screening methods enhance the efficiency of mining these libraries.
- Linking phage isolate binding data with antibody DNA sequences is essential for lead identification.
Purpose of the Study:
- To review recent approaches for high-throughput screening of phage antibody libraries.
- To describe information management challenges and solutions for antibody discovery.
- To enable rapid identification of potent drug leads from complex antibody libraries.
Main Methods:
- High-throughput screening of antibody clones from phage display libraries.
- Selection of clones based on binding to a defined antigen.
- DNA sequencing to determine antibody identity.
- Data management strategies for screening results.
Main Results:
- Recently reported approaches facilitate the mining of complex antibody libraries.
- Effective data management links phage isolate behavior to antibody identity.
- Streamlined processes enable rapid identification of promising drug leads.
Conclusions:
- Automated screening and robust data management are key to leveraging antibody phage display.
- Efficiently organizing screening data accelerates the drug discovery pipeline.
- These methods potentiate the identification of potent antibody drug leads.

